title: Inhibition of biliary lipid and protein secretion by cyclosporine A in the rat.
abstract: We investigated the effect of cyclosporine A (CyA) administered as a single i.v. dose of 20 and 40 mg/kg body wt, on biliary secretion of cholesterol, phospholipid, bile acid, and lysosomal marker and canalicular plasma membrane marker enzymes in anaesthetized Wistar rats. CyA reduced the concentration and biliary secretion of cholesterol, phospholipid and bile acid to a considerable extent; the inhibitory effect of CyA on the biliary secretion of phospholipid and bile acid was greater than that on cholesterol. The biliary outputs of acid phosphatase (AcP) and gamma-glutamyltransferase (gamma-GT) were also diminished by the drug, all these effects being dose-dependent. Maximum decreases in bile acid secretion were observed 10 min after administration, whereas those of cholesterol and phospholipid were delayed. Bile acid concentrations and secretion returned to pretest values at 30-50 min after CyA injection whereas those of cholesterol and phospholipid remained significantly reduced at this time point. The greater inhibitory effect of CyA on the biliary outputs of phospholipid and bile acid relative to cholesterol secretion together with the asynchronous fall and recovery of bile acid, cholesterol and phospholipid concentrations and secretion alter the cholesterol/bile acid, phospholipid/bile acid and cholesterol/phospholipid molar ratios as well as the lithogenic index, thus suggesting that CyA would uncouple biliary lipid secretion from bile acid secretion. Since under physiological conditions biliary lipid and gamma-GT secretion is related to and dependent upon bile acid secretion, we propose that the CyA-induced inhibition on lipid and gamma-GT secretion is, at least partly, secondary to the fall in bile acid output caused by the drug. However, since CyA inhibits secretory processes independent of the hepatobiliary flux of bile acid, such as the exocytic discharge of AcP, and because it also uncouples biliary lipid from bile acid secretion, other mechanisms and factors involved in lipid and protein secretion (such as intracellular transport, canalicular membrane fluidity and/or intracanalicular events) might also be altered by this drug.
authors.affiliation: Department of Physiology and Pharmacology, Universidad de Salamanca, Spain.
authors.forename: A I
authors.initials: AI
authors.lastname: Galán
authors.forename: I D
authors.initials: ID
authors.lastname: Román
authors.forename: M E
authors.initials: ME
authors.lastname: Muñoz
authors.forename: F
authors.initials: F
authors.lastname: Cava
authors.forename: J M
authors.initials: JM
authors.lastname: Gonzalez-Buitrago
authors.forename: A
authors.initials: A
authors.lastname: Esteller
authors.forename: R
authors.initials: R
authors.lastname: Jimenez
mesh_terms: D000818:Animals; D001646:Bile / Q000187:drug effects* / Q000378:metabolism; D001647:Bile Acids and Salts / Q000378:metabolism*; D001648:Bile Canaliculi / Q000201:enzymology; D002779:Cholestasis / Q000378:metabolism; D002784:Cholesterol / Q000378:metabolism*; D016572:Cyclosporine / Q000494:pharmacology*; D005217:Fat Emulsions, Intravenous / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010743:Phospholipids / Q000378:metabolism*; D011506:Proteins / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar
chemical_list: D001647:Bile Acids and Salts; D005217:Fat Emulsions, Intravenous; D010743:Phospholipids; D011506:Proteins; D016572:Cyclosporine; D002784:Cholesterol